Username:
Password:
Forgot Password?
Remember me
Alert me when new Journal Issues are available via Email Alert or RSS Feed
Decade: 2010-2019
Year: 2011
Issue: Vol 12 | No. 3 | November 2011 | Pages 265-288
Novel strategies for raising HDL-C: Pitavastatin in clinical practice
This supplement has been produced with the support of an unrestricted educational grant from Kowa Pharmaceutical Europe Co. Ltd.
Search Within This Issue
6 Articles:
Abstract: Lowering low-density lipoprotein-cholesterol (LDL-C) levels using statins can significantly reduce cardiovascular (CV) risk in patients with dyslipidemia. However, the risk of major vascular...
Abstract: Evidence that low-density lipoprotein-cholesterol (LDL-C) causes cardiovascular disease (CVD) is overwhelming. It has also been proven beyond all doubt that lowering the level of LDL-C using...
Abstract: Compared to other statins, pitavastatin is a highly potent 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor and an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-...
Abstract: Atherogenic dyslipidemia is characterised by high levels of triglycerides, low levels of high-density lipoprotein-cholesterol (HDL-C), and moderate to marked elevations in low-density lipopr...
Abstract: Although clinical trials provide useful information on drug safety and efficacy, results do not always reflect those observed in the real world. The Japanese long-term prospective post-marke...